Plain-English translation of NCT05922982 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After heart surgery, some patients develop a condition called vasoplegic shock where their blood vessels become too relaxed, causing dangerously low blood pressure. Doctors treat this with norepinephrine, a strong blood pressure medication. This trial tests whether a new monitoring device called the Acumen IQ can help doctors decide when it's safe to reduce or stop this medication more quickly, while preventing dangerous blood pressure drops.
Norepinephrine is necessary to save lives, but using it too long can cause harm. There's no clear way to know when it's safe to stop. This trial explores whether the new monitoring device can find the right moment to reduce the medication, improving recovery without risking complications.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either standard blood pressure monitoring or the new device-guided approach. Both groups will have their medication managed according to blood pressure readings, but the device group will also use the Acumen IQ monitor to guide decisions. The active monitoring lasts 72 hours, with follow-up visits at hospital discharge and 30 days after enrollment to check your recovery.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
France